Tonix Pharmaceuticals, a specialty pharma company focused on CNS disorders and based in New York City, has completed a reverse merger transaction through a share exchange agreement with publicly traded Tamandare Explorations Inc. Through a share exchange, the shareholders of Tonix acquired control of Tamandare.
In addition, Tamandare completed a private placement of $1.1 million to fund further R&D. Tamandare intends to change its name to Tonix Pharmaceuticals Holding Corp, and apply for a new...